AlloVir (NASDAQ:ALVR) just reported results for the second quarter of 2024. AlloVir reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -9 cents. The company ...

AlloVir, Inc. (ALVR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. Kalaris is a clinical-stage biopharmaceutical company ...

Shares of AlloVir (NASDAQ:ALVR) lost ~18% in the premarket on Friday after the cell therapy developer announced an all-stock merger agreement with clinical-stage biopharmaceutical company Kalaris ...

What is this Case About: AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies According to the complaint, in March 2022, AlloVir initiated global ...

AlloVir (ALVR) is scheduled to report earnings on March 14, 2025. The last reported earnings were for reported on November 12, 2024 for Q3.

AlloVir (NASDAQ:ALVR – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 13th.Analysts expect the company to announce earnings of ($2. ...

AlloVir (NASDAQ:ALVR) just reported results for the first quarter of 2024. AlloVir reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -18 cents. The company ...